Abstract
The clinical efficacy of ramatroban, a thromboxane A2 receptor antagonist, was investigated in 48 patients who consulted Masutani ENT Clinic in Osaka between January and May, 2001. Medication was administered and groups were stratified by start time.
In the peak period for Japanese cedar pollen scattering, the pre-treatment group demonstrated better control of nasal symptoms (sneeze, nasal mucus, and nasal obstruction) than the group that started the medication after Japanese cedar pollen scattering started.
Nasal obstruction has also improved by the medication for two weeks in patients who consulted the hospital with nasal obstruction after Japanese cedar and cypress pollen scattering had ended.
There were no side effects in any patients during ramatroban treatment.
Therefore, ramatroban was considered to be an effective medicine also not only for patients with perennial allergic rhinitis but also for patients with seasonal allergic rhinitis. It was thought that the nasal symptom of the pollen scattering period could be controlled by pre-treatment.
